List view / Grid view

Professor Matt Whiteman (MitoRx co-founder)

 

news

New data backs Myo4 for obesity treatment

MitoRx Therapeutics has announced new preclinical data for its small…

7 July 2025 | By

MitoRx Therapeutics has announced new preclinical data for its small molecule Myo4, showing restored insulin sensitivity and enhanced fat loss with muscle preservation in an obesity model - offering a potential alternative to GLP-1-based therapies.